Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

A Randomized Phase II Study of Oral Lenalidomide (Revlimid [TM]), an Antiangiogenic and Immunomodulatory Agent, in Subjects With Stage IV Ocular Melanoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00109005

Enrollment

Registered

2005-04-22

Start date

2005-04-30

Completion date

2009-04-30

Last updated

2017-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Keywords

Response Rate, Toxicity, Progression-Free Survival, Overall Survival, Pharmacokinetic, Ocular Melanoma

Brief summary

This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site). It will also examine the toxicity and blood effects of Revlimid. Patients 18 years of age and older with stage IV ocular melanoma may be eligible for this study. Candidates are screened with a medical history and physical and examination, blood and urine tests, electrocardiogram, chest x-ray, computed tomography (CT) scan and other imaging scans if needed, such as a bone scan, magnetic resonance imaging (MRI), ultrasound, or positron emission tomography (PET). Participants are admitted to the National Institutes of Health (NIH) Clinical Center for 24 hours for their first oral dose of Revlimid. During the hospital stay, blood is drawn before the dose is given and again at 0.25, 0.5, 1, 2, 4, 6, 9, 12 and 24 hours after dosing to see how the body handles the drug. If the drug is well tolerated, patients are sent home with a 21-day supply of drug to take once a day for 21 days, then go off drug 7 days. This regimen constitutes one 28-day treatment cycle. Treatment cycles may continue for up to 2 years. Patients keep a daily diary of side effects and have blood drawn once a week. The drug dose may be adjusted according to the laboratory test results. If unacceptable toxicity occurs, treatment may be stopped. Patients who agree to be biopsied undergo this procedure before treatment begins and at the end of treatment cycles 3 and 6. A small area of skin is numbed with medicine and a small piece of tumor is removed with a needle or by a small cut in the tumor. The tissue is examined under a microscope. Patients return to NIH after the first month of treatment and then every 3 months to evaluate their tumors and treatment of side effects. The visits include a physical examination, x-rays and scans to evaluate tumors. Visits are scheduled every 3 months while on treatment; then every 3 months for 2 years afterwards; then every 4 months for 1 year; and as needed after that. Patients will have a brain magnetic resonance imaging scan once a year to watch for new tumor areas.

Detailed description

Background: * Patients with stage IV ocular melanoma have very few available treatment options and an overall poor prognosis. * Pre-clinical and early clinical evidence suggest that lenalidomide has activity against solid tumors. * This trial is designed to evaluate the safety and efficacy of two different doses of a novel antiangiogenic and immunomodulatory agent, lenalidomide (Revlimid ). Objectives: Primary Objectives: * Determine the response rate to lenalidomide at two dose levels for patients with Stage IV ocular melanoma. * To determine the toxicity of lenalidomide at two dose levels in this setting. Secondary Objectives: * To determine the progression free and overall survival of patients with Stage IV ocular melanoma treated with lenalidomide. * When easily accessible, obtain tissue at baseline and during therapy to evaluate the effects of these agents on pathways, thought to be modulated by lenalidomide in pre-clinical studies. * To determine the pharmacokinetics of lenalidomide at these two doses in patients with Stage IV ocular melanoma. * To determine if there is a dose level with potentially superior efficacy and acceptable toxicity. Eligibility: * Patients \> 18 years of age with stage IV ocular melanoma, who have measurable disease. * Patient must be Eastern Cooperative Oncology Group (ECOG) performance status of = 2 and a life expectancy of more than 3 months. * Patients must have adequate organ function. * Patients must not have had prior surgery, chemotherapy, hormonal therapy, radiation therapy, or biological therapy for at least 4 weeks prior to starting study medication. * Patients who were receiving mitomycin C, nitrosoureas, or carboplatin must be 6 weeks from the last administration of chemotherapy. * Patients must not have an acute, critical illness,. * All patients who are sexually active and able to conceive will be required to use contraception during treatment with lenalidomide Design: * A phase II trial in which patients are randomized to 2 dose levels of lenalidomide administered for 21 days every 28 days for 2 years. * 76 patients (allowing for up to 3 inevaluable patients per dose level) will be enrolled over 4 to 5 years. * The objective of the trial will be to determine in each of the two groups of patients (5 mg and 25 mg dose levels) whether, CC5013 is able to be associated with a response rate (partial response (PR) + complete response (CR)) that can rule out 10% (p0=0.10) in favor of an improved response rate of 30% (p1=0.30).

Interventions

DRUGRevlimid

oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

-INCLUSION CRITERIA: 1. All patients with stage IV ocular melanoma, who have measurable disease will be considered. 2. Patients must have histopathological documentation of ocular melanoma confirmed in the Laboratory of Pathology/National Cancer Institute (NCI) of the Clinical Center at the National Institutes of Health. This can be from tissue obtained outside the National Institutes of Health (NIH). 3. Patient must be Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2. 4. Patients must have a life expectancy of more than 3 months. 5. Hematological eligibility parameters (prescreen): * Granulocyte count greater than 1,500/mm\^3 * Platelet count greater than 100,000/mm\^3 * If the creatinine is greater than 1.5 mg/dL, obtain a 24 hour urine collection. Creatinine clearance must be greater than 60 mL/min/1.73m\^2. * Hepatic function: bilirubin (total) less than or equal to 2.0 mg/dl; Alanine aminotransferase (ALT) less than 10 x upper limit of normal; Aspartate aminotransferase (AST) less than 10 x upper limit of normal. 6. Patients must have recovered from any acute toxicity related to prior therapy or surgery, to a grade 1 or less unless specified above. 7. Patients must not have had prior surgery, chemotherapy, hormonal therapy, radiation therapy, or biological therapy, for at least 4 weeks prior to starting study medication. Patients who were receiving mitomycin C, nitrosoureas, or carboplatin must be 6 weeks from the last administration of chemotherapy. 8. Patients must not have an acute, critical illness, including a serious untreated infection. 9. Patients must be willing to return to the National Institutes of Health (NIH) for follow-up visits. 10. All patients who are sexually active and able to conceive will be required to use contraception during treatment with lenalidomide. Only two criteria are allowed by the Food and Drug Administration (FDA) for the status of not of child bearing potential: hysterectomy or menopause for 24 consecutive months. Women of child bearing potential will be required to use two methods of birth control, one highly effective method and one additional method, at the same time during treatment and for one month after the completion of lenalidomide treatment. These methods must be used for at least four weeks before starting lenalidomide, during treatment, and for at least four weeks following the last dose of lenalidomide. Acceptable forms of birth control include: Intrauterine device (IUD) Latex condom Hormonal (Birth control pills, injections, implants) Diaphragm Tubal Ligation Cervical cap Partner's vasectomy Two barrier methods may be used if the physician agrees that the highly effective methods are medically contraindicated. Women of childbearing potential must have a negative urine pregnancy test 24 hours prior to the start of lenalidomide. Men who are sexually active must agree to use latex condoms. Patients must be able to understand and sign informed consent form. Patients must be greater than or equal to 18 years of age.

Exclusion criteria

1. Patients with evidence of active brain metastases will be excluded. Patients must have had a complete excision or radiotherapy and remain asymptomatic with stable disease as shown by magnetic resonance imaging (MRI) for at least six months. 2. Patients who are pregnant or lactating. No data is currently available about the excretion of lenalidomide in breast milk. Although no preclinical data suggest teratogenicity with this compound, because of the relationship to thalidomide, we will exclude patients who are pregnant or lactating. 3. Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment), New York class II-IV congestive heart failure, chronic obstructive lung disease requiring oxygen therapy or uncontrolled seizure activity are not eligible. 4. Patients who are known positive for human immunodeficiency virus (HIV) as it may increase their risk of infection since lenalidomide has effects on cells involved in the immune system. 5. Patients who have had prior therapy with lenalidomide. 6. Patients with known hypersensitivity reaction to lenalidomide.

Design outcomes

Primary

Measure	Time frame	Description
Clinical Responses in Patients With Metastatic Ocular Melanoma	12 months	Clinical response is assessed by the Response Evaluation Criteria for Adverse Events in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions. Progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Number of Participants With Adverse Events	24 months	Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.

Secondary

Measure	Time frame	Description
Determine Pharmacokinetics of Lenalidomide at Two Dose Levels: 5 mg and 25 mg	Prior to treatment on cycle 1, day 1 and then on cycle 1, day 1 at 0.25, 0.5, 1, 2, 4, 6, 9 and 12 hours. Cycle 1, day 2 at 24 hours.	Plasma samples will be obtained and plasma concentrations will be determined by a reversed-phase high-performance liquid chromatography (HPLC) assay using mass spectrometry (MS) detection.
Progression Free Survival	up to 2 years	Time interval from start of treatment to documented evidence of disease progression.
Evaluate Effects of Lenalidomide on Pathways	Baseline and at the end of treatment cycles 3 and 6. Every 21 day supply of lenalidomide with a 7 day rest (total of 28 days) will be considered a cycle of therapy.	Tissue will be obtained to evaluate the effects of lenalidomide on pathways thought to be modulated by lenalidomide.
Determine Dose Level With Superior Efficacy and Acceptable Toxicity	up to 2 years	The most efficacious dose (with greater number of responses) with acceptable toxicity profile will be considered for use in subsequent trials. iI the number of responses is tied, then toxicity criteria (Common Terminology criteria (CTC) v3.0) will be used to select the preferred dose.
Overall Survival	up to 2 years	Date of on-study to the date of death from any cause or last follow up.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Cohort 1 - 25 mg Lenalidomide (Revlimid) oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks	8
Cohort 2 - 5 mg Lenalidomide (Revlimid) oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks	9
Total	17

Baseline characteristics

Characteristic	Cohort 1 - 25 mg Lenalidomide (Revlimid)	Cohort 2 - 5 mg Lenalidomide (Revlimid)	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	0 Participants	2 Participants	2 Participants
Age, Categorical Between 18 and 65 years	8 Participants	7 Participants	15 Participants
Age, Continuous	51.7 years STANDARD_DEVIATION 7.6	58.86 years STANDARD_DEVIATION 9.83	55.56 years STANDARD_DEVIATION 9.71
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	8 Participants	9 Participants	17 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Gender Female	5 Participants	8 Participants	13 Participants
Gender Male	3 Participants	1 Participants	4 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	1 Participants	0 Participants	1 Participants
Race (NIH/OMB) Black or African American	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	7 Participants	9 Participants	16 Participants
Region of Enrollment United States	8 Participants	9 Participants	17 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	8 / 8	9 / 9
serious Total, serious adverse events	1 / 8	1 / 9

Outcome results

Primary

Clinical Responses in Patients With Metastatic Ocular Melanoma

Clinical response is assessed by the Response Evaluation Criteria for Adverse Events in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions. Progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame: 12 months

Population: Response data was combined for this outcome measure. Results are available for the combined cohorts only.~Sixteen out of seventeen patients were eligible for response assessments.

Arm	Measure	Group	Value (NUMBER)
Cohort 1 & 2 -25 mg & 5 mg Lenalidomide (Revlimid)	Clinical Responses in Patients With Metastatic Ocular Melanoma	Complete Response	0 Participants
Cohort 1 & 2 -25 mg & 5 mg Lenalidomide (Revlimid)	Clinical Responses in Patients With Metastatic Ocular Melanoma	Partial Response	0 Participants
Cohort 1 & 2 -25 mg & 5 mg Lenalidomide (Revlimid)	Clinical Responses in Patients With Metastatic Ocular Melanoma	Progressive Disease	9 Participants
Cohort 1 & 2 -25 mg & 5 mg Lenalidomide (Revlimid)	Clinical Responses in Patients With Metastatic Ocular Melanoma	Stable Disease	7 Participants

Primary

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.

Time frame: 24 months

Arm	Measure	Value (NUMBER)
Cohort 1 & 2 -25 mg & 5 mg Lenalidomide (Revlimid)	Number of Participants With Adverse Events	8 Participants
Cohort 2 - 5 mg Lenalidomide (Revlimid)	Number of Participants With Adverse Events	9 Participants

Secondary

Determine Dose Level With Superior Efficacy and Acceptable Toxicity

The most efficacious dose (with greater number of responses) with acceptable toxicity profile will be considered for use in subsequent trials. iI the number of responses is tied, then toxicity criteria (Common Terminology criteria (CTC) v3.0) will be used to select the preferred dose.

Time frame: up to 2 years